Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 2
2000 1
2001 2
2004 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Results by year

Filters applied: . Clear all
Page 1
Leuvectin Vical Inc.
Kaushik A. Kaushik A. Curr Opin Investig Drugs. 2001 Jul;2(7):976-81. Curr Opin Investig Drugs. 2001. PMID: 11757801 Review.
Vical's Leuvectin, a plasmid DNA expression vector encoding interleukin-2 (IL-2) complexed with a lipid delivery vehicle (DMRIE/DOPE)for intratumoral injection, is under development as a potential gene therapy for cancer. ...In November 2000, it was announced that Vical ha …
Vical's Leuvectin, a plasmid DNA expression vector encoding interleukin-2 (IL-2) complexed with a lipid delivery vehicle (DMRIE/DOPE) …
Intratumoral administration of a 1,2-dimyristyloxypropyl-3- dimethylhydroxyethyl ammonium bromide/dioleoylphosphatidylethanolamine formulation of the human interleukin-2 gene in the treatment of metastatic renal cell carcinoma.
Galanis E, Burch PA, Richardson RL, Lewis B, Pitot HC, Frytak S, Spier C, Akporiaye ET, Peethambaram PP, Kaur JS, Okuno SH, Unni KK, Rubin J. Galanis E, et al. Cancer. 2004 Dec 1;101(11):2557-66. doi: 10.1002/cncr.20653. Cancer. 2004. PMID: 15517589 Free article. Clinical Trial.
In the current study, the authors investigated the safety and efficacy of in situ vaccination with Leuvectin in patients with metastatic renal cell carcinoma. METHODS: Thirty-one patients with metastatic renal cell carcinoma were treated with intratumorally administered …
In the current study, the authors investigated the safety and efficacy of in situ vaccination with Leuvectin in patients with metasta …
Intratumoral interleukin 2 for renal-cell carcinoma by direct gene transfer of a plasmid DNA/DMRIE/DOPE lipid complex.
Hoffman DM, Figlin RA. Hoffman DM, et al. World J Urol. 2000 Apr;18(2):152-6. doi: 10.1007/s003450050189. World J Urol. 2000. PMID: 10854152 Clinical Trial.
In preclinical animal-safety studies, repeated administration of Leuvectin was safe and well tolerated. Following these promising preclinical trials, Leuvectin has been taken into clinical trial. The results of two early studies indicate that Leuvectin is saf …
In preclinical animal-safety studies, repeated administration of Leuvectin was safe and well tolerated. Following these promising pre …
Technology evaluation: interleukin-2 gene therapy for the treatment of renal cell carcinoma.
Figlin RA, Parker SE, Horton HM. Figlin RA, et al. Curr Opin Mol Ther. 1999 Apr;1(2):271-8. Curr Opin Mol Ther. 1999. PMID: 11715951 Review.
Leuvectin is a plasmid DNA/lipid complex comprised of a plasmid DNA expression vector (VCL-1102, 30) encoding human interleukin (IL)-2 complexed in a 5:1 mass ratio with DMRIE/DOPE lipid that has been developed for the treatment of cancer. ...In preclinical animal safety s
Leuvectin is a plasmid DNA/lipid complex comprised of a plasmid DNA expression vector (VCL-1102, 30) encoding human interleukin (IL)-
Interleukin 2 gene therapy for prostate cancer: phase I clinical trial and basic biology.
Belldegrun A, Tso CL, Zisman A, Naitoh J, Said J, Pantuck AJ, Hinkel A, deKernion J, Figlin R. Belldegrun A, et al. Hum Gene Ther. 2001 May 20;12(8):883-92. doi: 10.1089/104303401750195854. Hum Gene Ther. 2001. PMID: 11387054 Clinical Trial.
A functional DNA-lipid complex encoding the interleukin 2 (IL-2) gene (Leuvectin; Vical, San Diego, CA) was administered intraprostatically into the hypoecogenic tumor lesion, using transrectal ultrasound guidance. ...This phase I trial demonstrated the safety of intrapros …
A functional DNA-lipid complex encoding the interleukin 2 (IL-2) gene (Leuvectin; Vical, San Diego, CA) was administered intraprostat …
Immunotherapy of advanced malignancy by direct gene transfer of an interleukin-2 DNA/DMRIE/DOPE lipid complex: phase I/II experience.
Galanis E, Hersh EM, Stopeck AT, Gonzalez R, Burch P, Spier C, Akporiaye ET, Rinehart JJ, Edmonson J, Sobol RE, Forscher C, Sondak VK, Lewis BD, Unger EC, O'Driscoll M, Selk L, Rubin J. Galanis E, et al. J Clin Oncol. 1999 Oct;17(10):3313-23. doi: 10.1200/JCO.1999.17.10.3313. J Clin Oncol. 1999. PMID: 10506635 Clinical Trial.
PATIENTS AND METHODS: Twenty-four patients were treated in the phase I study. Leuvectin doses were 10 microg, 30 microg, or 300 microg weekly for 6 weeks. In three subsequent phase I/II studies, a total of 52 patients (18 with melanoma, 17 with RCC, and 17 with sarcoma) we …
PATIENTS AND METHODS: Twenty-four patients were treated in the phase I study. Leuvectin doses were 10 microg, 30 microg, or 300 micro …